Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
DRUG: Pemigatinib
Overall Response Rate (ORR) at Cycle 7 per IWG Response Criteria in subjects with R/R MCL., To assess the efficacy of pemigatinib in subjects with R/R MCL., 8 months|To determine the ORR at Cycle 7 per IWG Response Criteria in subjects with R/R MZL., To assess the efficacy of pemigatinib in subjects with R/R MZL., 8 months
Complete Response (CR) rate at Cycle 7 per IWG Response Criteria., To assess the CR rate at Cycle 7., 8 months|Duration of response (DoR), defined as the interval of time from the date of initial documented response (PR or better per IWG Response Criteria) to the time of progression from the best response, the start of a new therapy, or death from any cause., To assess the DoR of the study population., 4 years|Progression-free survival (PFS) as defined as the time from study drug initiation to the time documented disease progression (as assessed by IWG Response Criteria), or death from any cause., To assess median and 2 year PFS., 4 years|Overall survival (OS) as defined as the time from registration until death from any cause., To assess median and 2 year OS in this study population., 4 years
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.